J&J to buy Ollin Biosciences for $2.2 billion upfront; Blackstone to fund $750 million of Phase 3
Business Wire via StockTitan · · AI-summarised by FinFlash
Johnson & Johnson agreed to acquire eye-disease biotech Ollin Biosciences for $2.2 billion upfront plus up to about Positive for J&J's ophthalmology pipeline at limited balance-sheet cost; pressure on Regeneron and Roche franchises in retinal disease if OLN324 succeeds. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context